Takeda TYK2 drug tops Bristol Sotyktu
Decision brief
Answer first · skim in under a minute
Takeda’s TYK2 inhibitor zasocitinib outperformed Bristol Myers Squibb’s Sotyktu in a head-to-head plaque psoriasis trial. The result strengthens Takeda’s dermatology story and gives BD teams and investors a clearer read on the program’s competitive position.
Takeda TYK2 drug tops Bristol Myers Squibb’s Sotyktu (deucravacitinib) in Phase 3 LATITUDE Atlas (NCT06973291). Zasocitinib beat deucravacitinib on PASI 100 at week 16 in 606 adults with plaque psoriasis, per Takeda’s June 11, 2026 topline.
Contents9 sections
Key Takeaways
- Study: LATITUDE Atlas (TAK-279-PsO-3004; NCT06973291), Phase 3, n=606.
- Primary: PASI 100 at week 16—zasocitinib statistically superior to deucravacitinib.
- Company-reported: >35% PASI 100 on zasocitinib, more than 2.5× the deucravacitinib rate; curve separation by week 8.
- Sotyktu remains FDA-approved for plaque psoriasis (2022) at 6 mg once daily.
What did the head-to-head trial test?
LATITUDE Atlas randomized adults with moderate-to-severe plaque psoriasis to oral zasocitinib 30 mg once daily or deucravacitinib 6 mg once daily for up to 16 weeks. Total study participation could last up to 25 weeks including screening and safety follow-up. The primary endpoint was the percentage of participants achieving PASI 100 at week 16.
Registry details: ClinicalTrials.gov NCT06973291.
How large was the efficacy gap on PASI 100?
Takeda’s June 11, 2026 Business Wire release said zasocitinib showed statistical superiority on PASI 100 at week 16 and on all key secondary endpoints, including PASI 90 and Static Physician’s Global Assessment (sPGA) 0 at week 16. The company reported more than 35% of zasocitinib-treated patients achieved complete clearance—more than 2.5 times the deucravacitinib response—with separation as early as week 8.
Source: Takeda Business Wire — LATITUDE Atlas topline.
Where does Sotyktu sit as the comparator?
Sotyktu (deucravacitinib) is labeled as a TYK2 inhibitor for moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy, with initial U.S. approval in 2022. The labeled tablet strength is 6 mg—the same once-daily dose used as the active comparator in LATITUDE Atlas.
Label reference: DailyMed — SOTYKTU (deucravacitinib).
What it means for oral psoriasis pipelines
A positive head-to-head on complete clearance raises the bar for next-generation selective TYK2 inhibitors versus the first approved oral TYK2. Takeda said zasocitinib was generally well tolerated with no new safety signals in the topline disclosure and plans regulatory filings within the current fiscal year. Full datasets are slated for a future medical meeting.
Related entity pages: psoriasis hub, Takeda company page, and deucravacitinib drug page.
For BD and dermatology commercial teams, the practical read-through is comparative oral efficacy—not yet access. Formulary and prior-authorization battles will still hinge on labeled indication language, long-term safety, and head-to-head evidence quality once an NDA is filed. Until then, Sotyktu remains the only FDA-approved oral TYK2 option for plaque psoriasis in the United States.
What remains unproven
Topline superiority is not an FDA label. Exact PASI 100 percentages for the deucravacitinib arm, confidence intervals, and detailed adverse-event tables await full publication. Zasocitinib remains investigational and is not approved by any regulator.
Related NovaPharma coverage
- Psoriasis disease intelligence hub
- Deucravacitinib (Sotyktu) drug profile
- Takeda Pharmaceutical company hub
Frequently Asked Questions
What did LATITUDE Atlas show for zasocitinib vs Sotyktu?
In the Phase 3 LATITUDE Atlas head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for PASI 100 at week 16 (primary endpoint) and for key secondary endpoints including PASI 90 and sPGA 0 at week 16.
How large was the trial and what doses were used?
LATITUDE Atlas (NCT06973291) enrolled 606 adults with moderate-to-severe plaque psoriasis. Participants received zasocitinib 30 mg once daily or deucravacitinib 6 mg once daily for up to 16 weeks.
Is Sotyktu already approved for plaque psoriasis?
Yes. Sotyktu (deucravacitinib) is an FDA-approved oral TYK2 inhibitor indicated for moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy, with initial U.S. approval in 2022.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for zasocitinib.
Unlock full calendar →Takeda pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
